Home › Compare › FRTCF vs ABBV
FRTCF yields 20.41% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 2
Combined, FRTCF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FRTCF + ABBV for your $10,000?
Far East Consortium International Limited, an investment holding company, engages in the property development and investment, hotel operations and management, car park operations and facilities management, gaming and related operations, and securities and financial product investments. It develops a portfolio of residential properties; invests in retail and office buildings; and operates hotels. The company also operates third party and self-owned car parks; and owns and operates casinos and gaming facilities, as well as operated bars. In addition, it provides loan financing, sales agency, mortgage, administration and management, treasury management, vault, and hotel management and consultancy services. As of March 31, 2022, the company owned and operated 31 hotels with approximately 8,149 rooms; and managed 424 car parks with approximately 120,200 car parking bays. It has operations in Australia, New Zealand, Hong Kong, Malaysia, the Czech Republic, the People's Republic of China, Singapore, the United Kingdom, and the rest of Europe. The company was incorporated in 1990 and is based in Central, Hong Kong.
Full FRTCF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.